Omalizumab · Xolair

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Asthma, Chronic Spontaneous Urticaria

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
USProduct first approved 2003
JP
  • Treatment of bronchial asthma (for use only in patients with intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies)
Product first approved 2009PMDA
EU
  • Allergic asthma Xolair is indicated in adults, adolescents and children (6 to <12 years of age). Xolair treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma. Adults and adolescents (12 years of age and older) Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 <80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple...
Product first approved 2005EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (35)
Asthma
NCT01328886 · Novartis Pharmaceuticals
2011-03 – 2013-12 · Allergic Asthma
What this study did
NCT01202903 · Novartis Pharmaceuticals
2010-09 – 2013-10 · Persistent Allergic Asthma
What this study did
NCT01155700 · Novartis Pharmaceuticals
2010-06 – 2012-02 · Allergic Asthma
What this study did
NCT01007149 · Novartis Pharmaceuticals
2009-09 – 2011-02 · Asthma
What this study did
NCT00314574 · Genentech, Inc.
2005-12 – 2009-11 · Asthma
What this study did
NCT00500539 · Novartis
2007-07 – 2008-09 · Asthma
What this study did
NCT00396409 · Novartis Pharmaceuticals
2006-02 – 2008-08 · Allergic Asthma
What this study did
NCT00482248 · Novartis
2003-06 – 2006-06 · Asthma
What this study did
NCT00219323 · Novartis
2003-11 – 2006-03 · Asthma
What this study did
NCT00482508 · Novartis
2003-05 – 2005-10 · Asthma
What this study did
NCT00232050 · Novartis
2002-10 – 2005-05 · Asthma
What this study did
NCT00829179 · Duke University
2002-10 – 2004-07 · Allergic Asthma
What this study did
NCT00109200 · Genentech, Inc.
2003-05 – 2003-09 · Asthma
What this study did
Chronic Spontaneous Urticaria
NCT07816328 · Novartis Pharmaceuticals
2026-09-21 – 2028-05-24 · Chronic Spontaneous Urticaria
What this study did
NCT03328897 · Novartis Pharmaceuticals
2017-04-26 – 2019-09-24 · Chronic Spontaneous Urticaria
What this study did
NCT02161562 · Novartis Pharmaceuticals
2014-08-01 – 2016-11-03 · Chronic Spontaneous Urticaria
What this study did
NCT02329223 · Novartis Pharmaceuticals
2014-12 – 2015-12 · Chronic Spontaneous Uriticaria
What this study did
NCT01723072 · Novartis Pharmaceuticals
2013-01-23 – 2014-05-09 · Chronic Spontaneous Urticaria, Angioedema
What this study did
Other / comorbidity
NCT03881696 · National Institute of Allergy and Infectious Diseases (NIAID)
2019-07-22 – 2025-07-01 · Peanut Allergy, Multi-food Allergy
What this study did
NCT05390255 · Beijing Tongren Hospital
2022-05-25 – 2024-12-31 · Sinusitis
What this study did
NCT05774639 · Kashiv BioSciences, LLC
2023-08-15 – 2024-12-31 · Chronic Idiopathic Urticaria
What this study did
NCT04128176 · University of California, Davis
2017-03 – 2023-11-25 · Bullous Pemphigoid
What this study did
NCT03478930 · Hoffmann-La Roche
2018-05-09 – 2020-03-16 · Nasal Polyps, Chronic Rhinosinusitis
What this study did
NCT03280550 · Hoffmann-La Roche
2017-11-15 – 2019-03-11 · Nasal Polyps, Chronic Rhinosinusitis
What this study did
NCT03280537 · Hoffmann-La Roche
2017-11-21 – 2019-03-07 · Nasal Polyps, Chronic Rhinosinusitis
What this study did
NCT03369704 · Novartis Pharmaceuticals
2017-12-15 – 2018-10-20 · Seasonal Allergic Rhinitis
What this study did
NCT02166151 · Rabin Medical Center
2014-07 – 2016-06 · Chronic Idiopathic Urticaria
What this study did
NCT01294878 · Fondazione IRCCS Policlinico San Matteo di Pavia
2009-03 – 2010-10 · Interstitial Cystitis, Painful Bladder Syndrome
What this study did
Phase 2/3 (6)
Asthma
NCT02049294 · McMaster University
2014-03 – 2017-09 · Steroid and/or Prednisone Dependent Asthma, Eosinophilic Bronchitis
What this study did
NCT01976208 · Shanghai Zhangjiang Biotechnology Limited Company
2010-12 – 2015-12 · Allergic Asthma
What this study did
NCT01113437 · King's College London
2010-04 – 2012-08 · Bronchial Asthma
What this study did
NCT00180011 · DiMango, Emily, M.D.
2005-09 – 2012-02 · Asthma
What this study did
Chronic Spontaneous Urticaria
NCT01803763 · Insel Gruppe AG, University Hospital Bern
2012-09 – 2014-03 · Chronic Urticaria, Chronic Idiopathic Urticaria, Chronic Spontaneous Urticaria
What this study did
Other / comorbidity
NCT01333293 · University of Zurich
2011-09 – 2016-01 · Mastocytosis
What this study did
Phase 2 (41)
Asthma
NCT02570984 · Boston Children's Hospital
2018-11-27 – 2028-03-31 · Asthma
What this study did
NCT05332067 · Children's National Research Institute
2022-05-01 – 2028-03-01 · Asthma in Children, Atopy, Viral Upper Respiratory Infection
What this study did
NCT03727971 · Copenhagen University Hospital, Rigshospitalet
2019-01-01 – 2024-12-31 · Asthma, Infertility, Female
What this study did
NCT03074942 · Sociedad Española de Neumología y Cirugía Torácica
2017-04-20 – 2018-04-30 · Severe Asthma
What this study did
NCT02388997 · University of Virginia
2013-02-01 – 2017-05-04 · Asthma
What this study did
NCT01393340 · University Hospital, Ghent
2006-12 – 2009-12 · Nasal Polyposis, Asthma
What this study did
NCT00162773 · Johns Hopkins University
2005-04 – 2009-09 · Asthma
What this study did
NCT00434434 · Genentech, Inc.
2007-10 – 2009-06 · Allergic Asthma
What this study did
Other / comorbidity
NCT07059091 · Johns Hopkins University
2026-02-12 – 2031-05 · Chronic Obstructive Pulmonary Disease (COPD), Allergies
What this study did
NCT06943534 · Massachusetts General Hospital
2025-07-03 – 2028-04-01 · Allergies, Food Allergy
What this study did
NCT06934200 · Johns Hopkins University
2025-05-19 – 2027-10-15 · Food Hypersensitivity
What this study did
NCT04045301 · Philippe Bégin
2019-11-11 – 2026-06-05 · Food IgE-mediated Allergy, Immunotherapy, Omalizumab, Physiological Effects of Drugs
What this study did
NCT03679676 · Stanford University
2020-02-05 – 2025-05-02 · Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
What this study did
NCT04720612 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2021-10-15 – 2022-12-16 · Covid19
What this study did
NCT06103656 · New York Medical College
2016-08-20 – 2021-02-22 · Food Allergy
What this study did
NCT02879006 · Xiu-Min Li
2016-08 – 2020-11 · Food Allergy
What this study did
NCT02402231 · Caroline Nilsson
2013-10 – 2020-10 · Peanut Allergy
What this study did
NCT00890162 · National Institute of Allergy and Infectious Diseases (NIAID)
2009-04-27 – 2019-05-31 · Anaphylaxis, Hypotension, Bronchospasm, Angioedema
What this study did
NCT03181009 · Andrew Long, PharmD
2017-07-31 – 2019-01-30 · Food Allergy
What this study did
NCT01893658 · Mayo Clinic
2018-06-01 – 2018-09-28 · Acute Interstitial Nephritis
What this study did
NCT01713725 · Clinica Universidad de Navarra, Universidad de Navarra
2012-03 – 2017-06 · Chronic Urticaria
What this study did
NCT02012387 · Clinica Universidad de Navarra, Universidad de Navarra
2014-01 – 2017-06 · Cholinergic Urticaria
What this study did
NCT02626611 · Kari Christine Nadeau
2015-12 – 2016-11-16 · Food Allergy
What this study did
NCT01157117 · Hugh A Sampson, MD
2010-08 – 2015-10 · Milk Allergy
What this study did
NCT02262130 · Centre Hospitalier Universitaire de Besancon
2014-09-30 – 2015-09-29 · Solar Urticaria
What this study did
NCT01066104 · Massachusetts General Hospital
2009-12 – 2015-07 · Chronic Rhinosinusitis, Nasal Polyps
What this study did
NCT01580592 · Charite University, Berlin, Germany
2012-04 – 2015-02 · Cold Contact Urticaria
What this study did
NCT02169115 · Charite University, Berlin, Germany
2012-12 – 2014-12 · Symptomatic Dermographism
What this study did
NCT01003301 · Johns Hopkins University
2009-10 – 2013-09 · Cat Allergy
What this study did
NCT01599637 · Novartis Pharmaceuticals
2012-04 – 2013-09 · Chronic Idiopathic Urticaria
What this study did
NCT01179529 · Technical University of Munich
— · Atopic Dermatitis, Atopic Eczema
What this study did
NCT00949078 · Johns Hopkins University
2009-07 – 2011-08 · Food Allergy, Peanut Allergy
What this study did
NCT00851370 · National Jewish Health
2009-01 – 2011-02 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00123630 · University of Utah
2005-11 – 2010-01 · Esophagitis
What this study did
NCT00866788 · Genentech, Inc.
2009-03 – 2010-01 · Chronic Idiopathic Urticaria
What this study did
NCT00481676 · Novartis
2007-05 – 2009-04 · Chronic Urticaria
What this study did
NCT00382148 · Genentech, Inc.
2006-11 – 2008-06-28 · Peanut Hypersensitivity
What this study did
NCT00130234 · Johns Hopkins University
2004-11 – 2007-09 · Urticaria
What this study did
NCT00084097 · National Institute of Allergy and Infectious Diseases (NIAID)
2004-06-02 – 2007-02-05 · Gastroenteritis
What this study did
NCT00086606 · Genentech, Inc.
2004-06 – 2006-04 · Allergy
What this study did
NCT00078195 · National Institute of Allergy and Infectious Diseases (NIAID)
2003-04 – 2005-05 · Hay Fever, Hypersensitivity, Allergy, Rhinitis
What this study did
Phase 1/2 (4)
Other / comorbidity
NCT01781637 · Boston Children's Hospital
2013-01 – 2022-05-31 · Peanut Allergy, Food Allergy
What this study did
NCT02643862 · Stanford University
2015-03-18 – 2016-08-20 · Food Allergy
What this study did
NCT00932282 · University of North Carolina, Chapel Hill
2009-07 – 2015-08 · Peanut Hypersensitivity
What this study did
NCT01290913 · Lynda Schneider
2011-02 – 2013-09 · Peanut Allergy
What this study did
Phase 1 (14)
Asthma
NCT04778137 · Taizhou Mabtech Pharmaceutical Co.,Ltd
2020-12-01 – 2021-05-25 · Asthma
What this study did
Other / comorbidity
NCT04583501 · Johns Hopkins University
2020-12-15 – 2024-07-12 · Chronic Rhinosinusitis With Nasal Polyps, Nasal Polyps
What this study did
NCT04943744 · Stanford University
2021-05-17 – 2024-05-17 · Eosinophilic Disorder, Food Allergy
What this study did
NCT05053334 · Syneos Health
2022-02-16 – 2024-01-10 · Healthy Volunteers
What this study did
NCT05564611 · Kashiv BioSciences, LLC
2022-11-04 – 2023-08-15 · Healthy
What this study did
NCT04535817 · Beth Israel Deaconess Medical Center
2021-01-01 – 2022-01-01 · Autism Spectrum Disorder, Atopy
What this study did
NCT02266355 · Yale University
2014-11 – 2018-02-27 · Colon Cancer
What this study did
NCT02118987 · Dana-Farber Cancer Institute
2014-07 – 2017-12 · Drug Allergy
What this study did
NCT01716312 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2014-01-08 – 2017-08-24 · Systemic Lupus Erthematosus, Sjogren's Syndrome
What this study did
NCT00968110 · Boston Children's Hospital
2009-03 – 2017-04 · Milk Allergy
What this study did
NCT01510626 · Stanford University
2011-11 – 2015-12 · Immune System Diseases
What this study did
NCT01040598 · O & O Alpan LLC
2009-06 – 2011-12 · Eosinophilic Esophagitis
What this study did
NCT00260702 · National Institute of Allergy and Infectious Diseases (NIAID)
2005-11-24 – 2010-03-19 · Hyper-IgE Syndrome, Job's Syndrome
What this study did
NCT01678092 · Stanford University
2004-05 – 2006-12 · Atopic Dermatitis
What this study did
Phase 4 (58)
Asthma
NCT06027073 · Medical University of Silesia
2024-05-01 – 2028-03-01 · Asthma, Allergic
What this study did
NCT03476109 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2019-05-10 – 2024-12-31 · Severe Asthma
What this study did
NCT04998604 · Sanofi
2021-09-27 – 2024-12-27 · Chronic Rhinosinusitis With Nasal Polyps, Asthma
What this study did
NCT04585997 · University of Newcastle, Australia
2018-11-03 – 2022-12 · Asthma, Eosinophilic Asthma
What this study did
NCT04195958 · Genentech, Inc.
2020-11-30 – 2021-10-18 · Moderate-to-severe Allergic Asthma
What this study did
NCT02658877 · NYU Langone Health
2016-01 – 2018-07-19 · Asthma
What this study did
NCT02654145 · GlaxoSmithKline
2016-03-17 – 2017-05-31 · Asthma
What this study did
NCT02023151 · Johns Hopkins University
2013-02 – 2016-08 · Allergic Asthma
What this study did
NCT01922037 · Hoffmann-La Roche
2013-06-19 – 2016-03-31 · Asthma
What this study did
NCT01912872 · Novartis Pharmaceuticals
2013-11-11 – 2016-01-08 · Severe IgE-mediated Asthma
What this study did
NCT01430403 · National Institute of Allergy and Infectious Diseases (NIAID)
2011-09 – 2014-03 · Asthma
What this study did
NCT01125748 · Genentech, Inc.
2010-05 – 2013-08 · Allergic Asthma
What this study did
NCT01584687 · Instituto de Investigação em Imunologia
2012-06 – 2012-12 · Asthma
What this study did
NCT00367016 · University of California, Davis
2004-02 – 2012-10-17 · Asthma, Allergic Rhinitis, Atopic Dermatitis
What this study did
NCT00208234 · Creighton University
2004-01 – 2011-09 · Allergic Asthma
What this study did
NCT00567476 · Novartis
2007-11 – 2010-04 · Asthma
What this study did
NCT00870584 · Novartis Pharmaceuticals
2009-03 – 2010-03 · Persistent Allergic Asthma
What this study did
NCT00377572 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-10 – 2009-12 · Asthma
What this study did
NCT00777764 · Genentech, Inc.
2008-08 – 2009-04 · Healthy, Asthma
What this study did
NCT00242359 · Bernstein Clinical Research Center
2005-11 – 2009-01 · Allergy Induced Asthma
What this study did
NCT00283504 · Children's Hospital of The King's Daughters
2006-01 – 2009-01 · ALLERGIC ASTHMA
What this study did
NCT00264849 · Novartis
2005-11 – 2008-09 · Asthma
What this study did
NCT00546143 · Novartis
2007-07 – 2008-08 · Asthma
What this study did
NCT00454051 · Novartis Pharmaceuticals
2006-12 – 2008-03 · Asthma
What this study did
NCT00329381 · University of Mississippi Medical Center
2006-05 – 2007-10 · Asthma
What this study did
NCT00657891 · Creighton University
2007-03 – 2007-10 · Asthma
What this study did
NCT00133042 · University of Florida
2004-12 – 2006-12 · Asthma
What this study did
Chronic Spontaneous Urticaria
NCT05916937 · Simon Francis Thomsen
2024-01-12 – 2025-12-31 · Chronic Spontaneous Urticaria, Chronic Urticaria, Idiopathic
What this study did
NCT02550106 · Novartis Pharmaceuticals
2015-04-22 – 2016-01-11 · CHRONIC SPONTANEOUS URTICARIA
What this study did
Other / comorbidity
NCT07845552 · Johns Hopkins University
2026-10-19 – 2028-10 · Food Allergy
What this study did
NCT06618963 · National Jewish Health
2024-10-01 – 2026-12 · Food Allergy, Food Allergy in Children
What this study did
NCT06437171 · AAADRS Clinical Research Center
2024-06-03 – 2026-07-31 · Food Allergy
What this study did
NCT04774315 · University of Colorado, Denver
2022-01-01 – 2025-03 · Chronic Urticaria, Idiopathic
What this study did
NCT05405478 · Shiraz University of Medical Sciences
2022-06-01 – 2023-01-23 · Nasal Polyps
What this study did
NCT04037176 · Carsten Bindslev-Jensen
2019-11-01 – 2022-03-15 · Food Allergy
What this study did
NCT03964051 · Carsten Bindslev-Jensen
2019-07-01 – 2020-12-21 · Food Allergy
What this study did
NCT03111628 · Johns Hopkins University
2017-10-06 – 2020-05-01 · Urticaria Chronic
What this study did
NCT06806826 · Yuzuncu Yil University
2019-01-01 – 2020-03-01 · Allergic Rhinitis
What this study did
NCT02966314 · University of Wisconsin, Madison
2017-03-30 – 2020-01-06 · Idiopathic Angioedema
What this study did
NCT02742805 · Selina Gierer, D.O.
2016-02 – 2019-12 · Urticaria
What this study did
NCT02300701 · Guy's and St Thomas' NHS Foundation Trust
2014-12 – 2018-08 · Atopic Eczema, Atopic Dermatitis, Child
What this study did
NCT01701583 · University of Colorado, Denver
2013-04 – 2017-10 · Chronic Urticaria
What this study did
NCT02392624 · Genentech, Inc.
2015-05-18 – 2017-03-09 · Urticaria
What this study did
Early phase / not applicable (12)
Asthma
NCT03480815 · Chang Gung Memorial Hospital
2017-01-20 – 2020-06-30 · Severe Allergic Asthma
What this study did
NCT00286416 · Scripps Clinic
2006-01 – 2008-07 · Asthma, Allergic Rhinitis
What this study did
NCT00189228 · University of New Mexico
2005-09 – 2008-06 · Asthma
What this study did
NCT00226200 · University of Mississippi Medical Center
2004-11 – 2007-10 · Asthma
What this study did
NCT00287378 · University of North Carolina, Chapel Hill
2006-03 – 2007-07 · Asthma, Allergy
What this study did
Other / comorbidity
NCT05129033 · Shanghai Zhongshan Hospital
2021-11-15 – 2023-12-30 · Allergic Bronchopulmonary Aspergillosis
What this study did
NCT04489121 · Beijing Tongren Hospital
2020-07-28 – 2020-10-01 · Seasonal Allergic Rhinitis
What this study did
NCT02814630 · Asthma Inc Clinical Research Center
2016-09 – 2018-11-02 · Chronic Idiopathic Urticaria
What this study did
NCT02968394 · The University Clinic of Pulmonary and Allergic Diseases Golnik
2014-03 – 2017-03 · Allergy, Bee Venom, Immunotherapy, Omalizumab
What this study did
NCT02191072 · National Taiwan University Hospital
2014-07 – 2016-05 · Urticaria
What this study did
NCT03019237 · Medical University of Vienna
2012-11 – 2013-05 · Allergy
What this study did
NCT00604786 · Johns Hopkins University
2007-07 – 2009-01 · Allergic Rhinitis
What this study did
Used as active comparator (31)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (10)
Asthma
NCT05813470 · Cinnagen
2021-01-18 – 2023-01-15 · Allergic Asthma, Uncontrolled Moderate to Severe
What this study did
NCT04607629 · AO GENERIUM
2018-06-20 – 2019-12-13 · Bronchial Asthma
What this study did
Chronic Spontaneous Urticaria
NCT07946913 · Longbio Pharma
2026-12-07 – 2029-01-26 · Chronic Spontaneous Urticaria (CSU)
What this study did
NCT06365879 · Taizhou Mabtech Pharmaceutical Co.,Ltd
2024-06-18 – 2026-04-10 · Chronic Spontaneous Urticaria
What this study did
NCT04944602 · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
2021-07 – 2023-06 · Chronic Spontaneous Urticaria
What this study did
NCT04426890 · Celltrion
2020-12-09 – 2023-04-27 · Chronic Spontaneous Urticaria
What this study did
NCT03580369 · Novartis Pharmaceuticals
2018-10-17 – 2022-06-14 · Chronic Spontaneous Urticaria
What this study did
NCT03580356 · Novartis Pharmaceuticals
2018-10-20 – 2022-06-14 · Chronic Spontaneous Urticaria
What this study did
Other / comorbidity
NCT04976192 · Teva Pharmaceuticals USA
2021-08-30 – 2024-04-05 · Chronic Urticaria
What this study did
Phase 2 (7)
Asthma
NCT07342803 · Longbio Pharma
2025-01-25 – 2029-09-30 · Allergic Asthma
What this study did
NCT06438757 · Jemincare
2024-06-19 – 2025-12-20 · Allergic Asthma
What this study did
NCT01716754 · Novartis Pharmaceuticals
2012-12 – 2016-01 · Asthma
What this study did
Chronic Spontaneous Urticaria
NCT06509334 · Jemincare
2024-08-04 – 2026-07-15 · Chronic Spontaneous Urticaria
What this study did
NCT06228560 · Longbio Pharma
2024-01-26 – 2025-10-16 · Chronic Spontaneous Urticaria
What this study did
NCT04833855 · Amgen
2021-04-15 – 2023-04-13 · Chronic Spontaneous Urticaria
What this study did
NCT02477332 · Novartis Pharmaceuticals
2015-07-15 – 2017-06-12 · Chronic Spontaneous Urticaria
What this study did
Phase 1/2 (1)
Asthma
NCT01703312 · Novartis Pharmaceuticals
2012-11 – 2013-10 · Allergic Asthma
What this study did
Phase 1 (13)
Asthma
NCT06494345 · AO GENERIUM
2023-01-15 – 2024-06-09 · Allergic Asthma
What this study did
NCT01544348 · MedImmune LLC
2012-01 – 2013-06 · Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
What this study did
Chronic Spontaneous Urticaria
NCT05960708 · Yuhan Corporation
2023-08-23 – 2024-09-13 · Allergic Disease, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
What this study did
Other / comorbidity
NCT07356713 · Excellergy Inc.
2026-01-08 – 2026-12-07 · Allergic Disease
What this study did
NCT07246252 · Taizhou Mabtech Pharmaceutical Co.,Ltd
2024-03-28 – 2024-12-02 · Healthy Volunteers (HV)
What this study did
NCT05564221 · Yuhan Corporation
2022-11-01 – 2024-11-28 · Atopic Healthy Subjects, Adult Subjects With Allergic Diseases
What this study did
NCT05413161 · Kashiv BioSciences, LLC
2022-07-07 – 2023-06-30 · Healthy
What this study did
NCT05061524 · Yuhan Corporation
2021-09-26 – 2023-01-25 · Atopic Healthy Subjects, Adult Subjects with Mild Allergic Diseases
What this study did
NCT05449535 · Jemincare
2022-05-07 – 2023-01-10 · Healthy
What this study did
NCT05897008 · Taizhou Mabtech Pharmaceutical Co.,Ltd
2022-02-07 – 2022-09-13 · Healthy Volunteers
What this study did
NCT04361812 · BioRay Pharmaceutical Co., Ltd.
2020-10-15 – 2021-12-31 · Similarity of Pharmacokinetics and Safety
What this study did
NCT04018313 · Celltrion
2020-05-28 – 2021-04-30 · Healthy
What this study did
NCT04601389 · AO GENERIUM
2017-04-18 – 2017-09-06 · Healthy Volunteers
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Asthma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Omalizumab (Xolair): this drugApprovedMonoclonal antibodyIgE, IgE (immunoglobulin E)Weak signalNo reviewed efficacy summary in this indication
Albuterol (Armstrong Albuterol HFA)ApprovedSmall moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Albuterol (Ventolin)ApprovedSmall moleculeBeta-2 adrenergic receptorWeak signalNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)ApprovedCombinationBeta-2 adrenergic receptor, Glucocorticoid receptorReliable signal
NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212
NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056
Albuterol Sulfate (Amphastar)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol Sulfate (Proventil HFA)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
AminophyllineApprovedSmall moleculePhosphodiesterase (multi-subtype)not yet gradedNo reviewed efficacy summary in this indication
Beclomethasone (QVAR)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results).
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
Benralizumab (Fasenra)ApprovedMonoclonal antibodyIL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophilsReliable signal
NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24)
NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001).
Budesonide (Pulmicort)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Pulmicort Flexhaler)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027).
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicPartial signal
NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014)
NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015)
Ciclesonide (Alvesco)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone
NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis
DepemokimabApprovedMonoclonal antibodyIL-5Partial signal
NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58)
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414).
Fluticasone Furoate (Arnuity Ellipta)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409)
NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001).
NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321)
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorReliable signal
NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010
NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998)
Fluticasone PropionateApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed
Fluticasone Propionate / Salmeterol (Advair HFA)ApprovedCombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptorPartial signal
NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53)
Levalbuterol (Xopenex HFA)Approved—beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingWeak signal
NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66
NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale)ApprovedSmall moleculeGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001.
NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001.
Montelukast (Singulair)ApprovedSmall moleculeCysteinyl leukotriene receptor 1 (CysLT1)Weak signal
NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin.
Primatene MistApprovedSmall moleculeAdrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselectivePartial signal
NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed
NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64).
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
TerbutalineApprovedSmall moleculeBeta-2 adrenergic receptor (ADRB2)not yet gradedNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)ApprovedMonoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingReliable signal
NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39)
NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed
Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026)
NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5)
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptorReliable signal
NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206)
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
FenoterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Fenoterol / Ipratropium BromidePhase 3Small moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorReliable signal
NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo.
Indacaterol Maleate / Mometasone FuroatePhase 3—Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016)
NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134)
IpratropiumPhase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010)
NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL
OcankitugPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
Oxitropium Bromide (Ba253BINEB)Phase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Salbutamol HFA-152aPhase 3Small moleculeBeta-2 adrenergic receptorWeak signal
NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results).
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VilanterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signal
NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036)
Glycopyrronium (PT001)Phase 2/3Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412)
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2/3Monoclonal antibodyTSLPWeak signalFeatured results are safety only in this race
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
ARO-RAGEPhase 2RNA / oligonucleotideRAGE (receptor for advanced glycation end-products)Weak signalFeatured results are safety only in this race
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Freneslerbart / MevonlerbartPhase 2Monoclonal antibodyFel d 1 (major cat allergen protein)Reliable signal
NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083
FrevecitinibPhase 2Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13Weak signalFeatured results are safety only in this race
PBF-680Phase 2—Adenosine A1 receptorPartial signal
NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1)
QuisovalimabPhase 2Monoclonal antibodyLIGHT (TNFSF14)Partial signal
NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication
BriquilimabPhase 1Monoclonal antibodyKITPartial signalFeatured results are safety only in this race
Ozureprubart
—(overall)
Monoclonal antibodyIgE
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 26 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Xolair (Omalizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Phase 2Food HypersensitivityRecruiting
Est. primary completion 2027-04-15 · NCT06934200 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Allergies, Food AllergyRecruiting
Est. primary completion 2027-05-01 · NCT06943534 · CT.gov ↗
What to watch
2028 (4)
January 2028 (2)
Phase 2AsthmaRecruiting
Est. primary completion 2028-01-01 · NCT05332067 · CT.gov ↗
What to watch
Phase 2AsthmaActive not recruiting
Est. primary completion 2028-01-31 · NCT02570984 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Chronic Spontaneous UrticariaRecruiting
Est. primary completion 2028-05-24 · NCT07816328 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4Food AllergyRecruiting
Est. primary completion 2028-10 · NCT07845552 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Phase 2Chronic Obstructive Pulmonary Disease (COPD), AllergiesRecruiting
Est. primary completion 2031-01 · NCT07059091 · CT.gov ↗
What to watch

See the full readout calendar ↗